UNAIR NEWS – Universitas Airlangga (UNAIR) inaugurated its professors on Thursday, December 19, 2019. This time UNAIR Vice Rector IV Prof. Junaidi Khotib, S.Si., M. Kes., Ph.D. was inaugurated as Professor of Biopharmaceutical Science.
Prof. Junaidi has officially become 25th Professor of Faculty of Pharmacy UNAIR. Being inaugurated in Garuda Mukti Hall, UNAIR Campus Management Office C, Prof. Junaidi delivered his inaugural remarks entitled “Engineering Development of Safe and Quality Erythropoietin Products “.
“A pharmacist is a noble profession and it always puts quality in providing services to the community based on science, experience, ethics, and law,” stated Prof. Junaidi quoting some parts of a pharmacist’s code of ethics.
Prof. Junaidi believed that the medicine given must meet safety and quality requirement so that it can provide benefits to the community. According to him, the quality of medicinal products has an important role to provide security and guarantee success of a treatment.
“Therefore, whether we realize it or not, quality assurance of raw materials, production processes to post-market supervision is absolutely necessary to maintain the quality of medicinal products in circulation,” he explained.
Furthermore, Prof. Junaidi explained that Erythropoietin (EPO) as an anti-anemia in kidney failure is an example of a product referring to the biological system of life. EPO itself has neuroprotective properties (a mechanism used to protect nerve damage in central nervous system) which is very promising.
Prof. Junaidi and team conducted an evaluation of today’s biopharmaceuticals regarding how to assess the resulted products whether they are safe and effective. According to him, there are four parameters of measurements.
“The four parameters are legal status, technological approach, market opportunity and economic value,” he added.
To be an EPO product that provides safety and quality, a quality by design approach must be used. The design from upstream to downstream process at each stage, the quality of the drug must be maintained.
Prof. Junaidi also said that there are four stages that must be passed. First, overall characterization of EPO raw materials and products. Then formulation, non-clinical evaluation and finally clinical evaluation in an effort to ensure the safety and quality of biopharmaceutical products.
“These efforts must be carried out comprehensively and thoroughly so it will provide the maximum benefit for humanity,” he concluded.
Author: Sandi Prabowo
Editor: Nuri Hermawan
